Human induced pluripotent stem cells: A review of the US patent landscape

Regenerative Medicine

Volumn 5, Issue 4, 2010, Pages 581-591

  Georgieva, Bilyana P ^a   Love, Jane M ^a  

^a WILMER CUTLER PICKERING HALE AND DORR LLP   (United States)

Author keywords

claim; embryonic stem cell; enablement; induced pluripotent stem cell; nonobviousness; novelty; patent rights; patentability; pluripotent

Indexed keywords

KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

BIOTECHNOLOGY; CELL CULTURE; CELL DIFFERENTIATION; CELL RENEWAL; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; GENETIC MANIPULATION; GENETIC VARIABILITY; HUMAN; LAW; PATENT; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SOMATIC CELL; UNITED STATES; UPREGULATION;

HUMANS; INDUCED PLURIPOTENT STEM CELLS; PATENTS AS TOPIC; REGENERATIVE MEDICINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954777572     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.10.43     Document Type: Review

References (57)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al.: Embryonic stem cell lines derived from human blastocysts. Science 282(5391), 1145-1147 (1998).
2. Shamblott MJ, Axelman J, Wang S, et al.: Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl Acad. Sci. USA 95(23), 13726-13731 (1998).
3. Gearhart J: A decade of stem-cell research. An interview with John Gearhart, Director of the Institute for Regenerative Medicine at the University of Pennsylvania, USA. Interview by Howard Wolinsky. EMBO Rep. 10(1), 12-16 (2009).
4. Takahashi K, Tanabe K, Ohnuki M, et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007).
5. Yu J, Vodyanik MA, Smuga-Otto K, et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858), 1917-1920 (2007).
6. Kang L, Wang J, Zhang Y, Kou Z, Gao S: IPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell 5(2), 135-138 (2009).
7. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K: Induced pluripotent stem cells generated without viral integration. Science 322(5903), 945-949 (2008).
8. Yu J, Hu K, Smuga-Otto K, et al.: Human induced pluripotent stem cells free of vector and transgene sequences. Science 324(5928), 797-801 (2009).
9. Zhou H, Wu S, Joo JY, et al.: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4(5), 381-384 (2009).
10. Huangfu D, Osafune K, Maehr R, et al.: Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol. 26(11), 1269-1275 (2008).
11. Ichida JK, Blanchard J, Lam K, et al.: A small-molecule inhibitor of TGF-b signaling replaces Sox2 in reprogramming by inducing Nanog. Cell Stem Cell 5(5), 491-503 (2009).
12. Webb S: The gold rush for induced pluripotent stem cells. Nat. Biotechnol. 27(11), 977-979 (2009).
13. United States Code (USC). Title 35: Patent Statute.
14. European Patent Office: Enlarged Board of Appeal of the European Patent Office decision. G0002/06, 26 November 2008.
15. Bilski v. Doll, 545 F.3d 943 (Fed.Cir. 2008), petition for writ of certiorari to the US Court of Appeals for the Federal Circuit granted, 129 S.Ct. 2735 (US 2009).
16. Assn for Molecular Pathology, et al. v. US PTO, et al., 2010 WL 1233416 (S.D.N.Y. 2010).
17. Doi A, Park IH, Wen B, et al.: Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41(12), 1350-1353 (2009).
18. Chin MH, Mason MJ, Xie W, et al.: Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5(1), 111-123 (2009).
19. Baker M: Stem cells: fast and furious. Nature 458(7241), 962-965 (2009).
20. SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312, 1319 (Fed.Cir. 2006).
21. Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282, 1293 (Fed.Cir. 2009).
22. Hwang WS, Ryu YJ, Park JH, et al.: Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. Science 303(5664), 1669-1674 (2004).
23. Kennedy D: Editorial retraction. Science 311(5759), 335 (2006).
24. Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., 560 F.3d 1366 (Fed.Cir. 2009), petition for rehg granted, 332 Fed.Appx. 636 (Fed. Cir. 2009).
25. Park IH, Zhao R, West JA, et al.: Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451(7175), 141-146 (2008).
26. Hanna J, Markoulaki S, Schorderet P, et al.: Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133(2), 250-264 (2008).
27. Wisconsin Alumni Research Foundation: US5843780C1 (2008).
28. Wisconsin Alumni Research Foundation: US6200806C1 (2008).
29. Jaenisch R, Hochedlinger K: US7682828 (2010).
30. Sakurada K, Masaki H, Ishikawa T, Takahashi S: GB2450603 (2010).
31. iZumi Bio, Inc.: WO2009006930 (2009).
32. iZumi Bio, Inc.: WO2009006997 (2009).
33. iZumi Bio, Inc.: WO2009007852 (2009).
34. Sakurada K: US20090299763 (2009).
35. Sakurada K, Seidenman KJ: US20090324559 (2009).
36. Yamanaka S: JP04183742 (2008).
37. Yamanaka S, Takahashi K, Nakagawa M: US20090047263 (2009).
38. Yamanaka S, Koyanagi M: US20090246875 (2009).
39. Thomson J, Yu J: US20080233610; WO2008118820 (2008).
40. Mack A, Thomson J: US20100003757 (2010).
41. Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GMBH): WO2009115295 (2009).
42. Nevada Cancer Institute: WO2009092042 (2009).
43. The Scripps Research Institute: WO2009117439 (2009).
44. President and Fellows of Harvard College: WO2009102983 (2009).
45. Mirae Biotech Co., Ltd.: WO2009096614 (2009).
46. Childrens Medical Center Corporation: WO2009061442 (2009).
47. Whitehead Institute for Biomedical Research: WO2009032194 (2009).
48. Whitehead Institute for Biomedical Research: WO2008124133 (2008).
49. The General Hospital Corporation: WO2008151058 (2008).
50. Primegen Biotech LLC: WO2009032456 (2009).
51. Jonannes Gutenberg-Universitat Mainz: WO2009077134 (2009).
52. Lin S, Ying S, Wu DTs: US20080293143 (2008).
53. Wisconsin Alumni Research Foundation: US7029913 (2006).
54. Executive Order of March 9, 2009: Removing barriers to responsible scientific research involving human stem cells, 74 Federal Register 10667 11 March (2009) www.archives.gov/federal-register/ executive-orders/2009-obama.html
55. NIH Guidelines for Human Stem Cells Research, 2009 http://stemcells.nih. gov/ policy/2009guidelines.htm
56. Section 509, Omnibus Appropriation Act, 2010, HR3288.ENR. Pub. L. 111-117, December 16, 2009; known as the Dickey-Wicker Amendment, re-enacted annually by Congress, original rider can be found in Section 128 of PL 104-199, 110 Stat. 26, 34 (1996) http://thomas.loc.gov/cgi-bin/ bdquery/D?d111:3:./temp/ ~bdjTyD::|/home/ LegislativeData.php|
57. Stein R: US set to fund more stem cell study www.washingtonpost.com/wp- dyn/content/ article/2009/12/02/AR2009120201955.html